Glooko announced today that it expanded the position of Dr. Mark Clements to make him its chief medical and strategy officer.
Clements became the Palo Alto, California-based diabetes management company’s fractional chief medical officer in 2016. He now steps into an expanded, full-time role designed to integrate Glooko’s clinical vision, product roadmap and data solutions. His appointment aims to accelerate growth and innovation, according to a news release.
“Dr. Clements’ expertise as an endocrinologist, coupled with his deep experience in diabetes digital health, remote patient monitoring, data integration, AI and machine learning, and clinical trial design, uniquely positions him to align clinical insights directly with Glooko’s product and service offerings,” said Mike Alvarez, CEO of Glooko.
In addition to his position with Glooko over the past decade, Clements most recently served as professor of pediatrics at the University of Missouri-Kansas City (UMKC) School of Medicine. There, he held the Endowed Chair in Endocrinology and Diabetes. Clements also led the Diabetes Research Program there.
“As a long-time advisor to Glooko and an active user of the platform in my clinical practice, I’ve witnessed firsthand how Glooko helps clinical teams consistently deliver measurable improvements in diabetes care outcomes,” said Dr. Clements. “As we look to the future, precision engagement and population health insights will be key focuses of the company and our platform. We are investing in making it easier for healthcare providers to connect people with diabetes to the Glooko platform, reducing clinical staff burden, optimizing clinician time, helping them stay at the top of their scope of practice, and personalizing interventions. This is a pivotal moment for our company and for diabetes care delivery overall, and I am confident Glooko’s best-in-class technology will continue to improve how diabetes care is delivered.”
